Last reviewed · How we verify
niacin extended-release (NER)
At a glance
| Generic name | niacin extended-release (NER) |
|---|---|
| Also known as | Niaspan, ABT-919 |
| Sponsor | Abbott |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin (PHASE3)
- Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- niacin extended-release (NER) CI brief — competitive landscape report
- niacin extended-release (NER) updates RSS · CI watch RSS
- Abbott portfolio CI